Kornimate/medical-research-clean huggingface dataset:
processed meat and colon carcinogenesis

Conditions: Colorectal Cancer

Summary: colorectal cancer kills forty five people in france every day. epidemiological studies suggest that two cases out of three could be prevented and show that processed meat intake is a consistent risk factor. the aim of this study is to understand how meat promotes cancer, to find protective strategies, and to make compelling dietary recommendations.

18 healthy volunteers will be randomized and will start the study. the study will last 4 weeks for each subject. the first week will be a week of adaptation (or run-in period) to the diet which they will have to follow for the duration of study. during this period, they will collect 2 samples of stools and urine. then subjects will alternate 4 days of diet either with ham, or with ham and calcium, or with ham enriched with vitamin e. at least, 3 days will separate every period (wash-out) of nutritional intervention. urines and stools will be collected last 3 days of every interventional period and also last day of every wash out period.

Eligibility criteria:
inclusion criteria: * male * body mass index 20 \<= bmi \<= 30 kg/m2 * affiliated to french national health insurance * subject giving his written informed consent * subject considered as normal after clinical examination and medical questionnaire exclusion criteria: * positive serologies to hiv or hcv, determined on blood samples * previous medical and/or surgery judged by the investigator as incompatible with this study * previous familial of colon, ovarian or breast cancer * chronic pathologies : cardiovascular diseases, cancer, chronic inflammation diseases, renal, intestinal impairments * dislike ham * heavy consumer of alcohol * practising intensive physical exercise * being under someone's supervision * refusal to be registered on the national volunteers data file * dietary habits unreliable to controlled food intake * being in exclusion on the national volunteers data file

Keywords: colorectal cancer processed meat calcium vitamin e preventive strategies
feasibility of cough monitoring in children

Conditions: Cystic Fibrosis in Children

Summary: cystic fibrosis (cf) is a disease characterized by chronic airway infection and impaired mucociliary clearance, which predisposes those affected to recurrent pulmonary exacerbations (pex) and progressive decline in lung function. treatment with elexacaftor/tezacaftor/ivacaftor (eti) results in decreases in patient-reported cough and pex. despite this, increased cough remains the most common symptom associated with acute pex and worsening lung disease. cough frequency was historically difficult to measure due to reliance on human input. recent advances in audio capture and signal processing have made automated cough detection possible. as a result there's been a surge in development of portable cough monitors, as cough is increasingly recognized as a measurable parameter of respiratory disease. the majority of cough monitors have been designed for use in adults, and little is known about the practicality of collecting cough data in the pediatric population. in this study investigators aim to assess the feasibility of using an in-home device to capture nighttime cough frequency in children with and without cf. investigators plan to compare nighttime cough frequency between children with and without cf and, among children with cf, and determine the association between cough frequency and baseline lung function. additionally, investigators aim to evaluate the changes in nighttime cough frequency in relationship to respiratory symptom scores surrounding clinician diagnosed pulmonary exacerbations. this study will provide important preliminary data needed for a larger study assessing the utility of home cough monitoring for clinical care and for use of cough as a clinical outcome measure in research studies.


Eligibility criteria:
inclusion criteria for children with cystic fibrosis * diagnosis of cf based on 2 known cftr mutations and/or sweat chloride \> 60 mmol/l * ages 1-18 years of age * clinically stable at the time of consent exclusion criteria * use of nocturnal positive pressure or supplemental oxygen * shared bedroom with sibling * use of oral or iv antibiotics within the past 2 weeks except for chronic azithromycin use * shared custody (i.e., the participant is splitting time between time households) inclusion criteria for healthy controls * ages 1-18 exclusion criteria: * shared bedroom with sibling * underlying chronic respiratory or cardiac conditions including chronic cough, cf, asthma, obstructive sleep apnea, or congenital heart disease or other condition felt by the investigator to cause chronic nighttime symptoms * shared custody (i.e., the participant is splitting time between time households)
transcranial direct current stimulation (tdcs) as therapeutical strategy for negative symptoms in schizophrenia

Conditions: Transcranial Direct Current Stimulation; Schizophrenia

Summary: the current research is aimed at using transcranial direct current stimulation (tdcs) as complementary therapeutic tool in the treatment of schizophrenia. patients will be randomized into two groups (tdcs-active x tdcs-sham) accordingly to detailed protocol. main outcome will be measured by specific clinical rating scales based on the assessment of negative symptoms. a total of 40 patients ought to be enrolled as specified in methodology. secondary outcomes shall include collateral effects evaluation, anxiety and depressive scales as well as clinical monitoring.

overview the present study is a double-blind randomized clinical trial in which patients should be allocated from a general psychiatry service into two groups (tdcs-active x tdcs-sham). subjects who fulfilled eligibility criteria will undergo ten days of consecutive stimulation (active or sham) and will return after two to four weeks for final clinical assessment. patients who shown no response in rating scales and that were allocated to sham intervention group will be able to choose whether or not they want to undergo the active intervention at follow up (partial cross-over)

Eligibility criteria:
inclusion criteria: * patients with age between 18-59 years * diagnostic of schizophrenia or schizoaffective disorder as stated by dsm-iv and confirmed by scid (structured clinical interview for dsmiv), to be tested by a psychiatrist * baseline score higher than 20 for negative symptoms at paan * patients able to read and understand portuguese. exclusion criteria: * other psychiatric diagnosis * criteria for bipolar disorder; dementia; other psychotic disturbs; substance related disorders * presence of other severe neurological or clinical diseases * presence of suicidal behavior (planning or attempt in the previous 4 weeks) * pregnancy * incapacity of coping with the informed consent * specific tdcs limitations (such as anatomic problems) regarding medication: all patients should have stable dosology of medications for at least 6 weeks

Keywords: transcranial direct current stimulation schizophrenia
paclitaxel and oxaliplatin in treating patients with recurrent or advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining paclitaxel and oxaliplatin in treating patients who have recurrent or advanced non-small cell lung cancer.

objectives: i. determine the overall, partial, and complete response rates in patients with advanced non-small cell lung cancer treated with oxaliplatin plus paclitaxel. ii. assess the overall survival, time to tumor progression, and toxicities associated with this combination regimen in this patient population. iii. assess the neurologic toxicity of this combination regimen and its correlation with creatinine clearance in these patients. outline: this is a multicenter study. patients receive paclitaxel iv over 1 hour followed by oxaliplatin iv over 2 hours on day 1. treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. patients are followed for at least 2 years or until death. projected accrual: approximately 17-37 patients will be accrued for this study within 24 months.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed non-small cell lung cancer (nsclc) stage iiib with pleural effusion or stage iv or recurrent disease bidimensionally measurable disease patient characteristics: age: 18 and over performance status: ecog 0-2 karnofsky 50-100% life expectancy: not specified hematopoietic: wbc greater than 3,000/mm3 absolute neutrophil count at least 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin normal sgot less than 2 times normal renal: creatinine no greater than 1.5 mg/dl or creatinine clearance at least 50 ml/min bun less than 1.5 times normal cardiovascular: no symptomatic congestive heart failure no unstable angina or myocardial infarction within the past 6 months no evidence of heart block greater than first degree, bundle branch block, or ventricular or supraventricular arrhythmia other: no allergy to platinum compounds or antiemetics appropriate for study no other uncontrolled illness no active or ongoing infection no evidence of peripheral neuropathy by physical exam or history not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 6 months after study prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for advanced nsclc at least 4 weeks since prior chemotherapy endocrine therapy: not specified radiotherapy: at least 4 weeks since prior radiotherapy surgery: not specified other: no other concurrent investigational agents no concurrent antiretroviral therapy for hiv positive patients

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
treatment of periodontal intra-bony defects with a volume stable collagen matrix or deproteinized bovine bone mineral with 10% collagen

Conditions: Periodontal Diseases

Summary: to compare the healing of intrabony periodontal defects treated with either open flap debridement and a volume-stable collagen matrix (vcmx) or a deproteinized bovine bone mineral with 10% collagen. the results will shed light on the clinical potential of vcmx in regenerative periodontal surgery and help to develop new treatment strategies.


Eligibility criteria:
inclusion criteria * patients with localized or generalized periodontitis stage iii and stage iv, grade a-b-c * males and females * age at least 18 years and older * presence of interdental intra-bony defects (i, ii and iii walls) in either the maxilla or the mandible with a pd ≥ 6 mm * defects with an intra-bony component \&gt; 3 mm for both groups * intra-bony defect located only at one aspect (mesial or distal) * presence of at least 2 mm of keratinized soft tissue. exclusion criteria * patients with systemic disease that could interfere with periodontal wound healing * prolonged antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery * pregnant or lactating * smokers with \&gt; 10 cig./day * patients with fmps and fmbs \&gt; 25 % after completion of non-surgical periodontal therapy * multi-rooted teeth with furcation involvement * third molars * teeth with circumferential defects * interdental craters * written informed consent
insulin resistance in type i diabetes in pediatric care

Conditions: Type 1 Diabetes

Summary: 24 children (12 african-american, hispanic, or american indian, 12 caucasian) previously diagnosed with type 1 diabetes mellitus will participate in this pilot study to evaluate the presence of hepatic and peripheral insulin resistance. the investigators will use this pilot information to test the hypothesis that insulin resistance occurs in some children with type 1 dm, is secondary to underlying risk factors, and is responsible for increased insulin needs. methods will include a "step-up" hyperinsulinemic euglycemic clamp and infusion of the stable isotope 6,6-\[2h2\]-glucose. patient and parent interviews will be conducted to gather information about nutritional intake, ethnicity, family history, and socioeconomic status. the investigators will also measure inflammatory cytokines and free fatty acids to determine whether they are associated with differences in insulin resistance among type 1 diabetes mellitus patients.


Eligibility criteria:
inclusion criteria: * previously diagnosed with type 1 diabetes * ages 9 -11 tanner 1 or 16-23 tanner 4-5 exclusion criteria: * none
pathogenesis of functional hypothalamic amenorrhea

Conditions: Disorder of Endocrine Ovary; Hypersecretion; Cortisol; Metabolic Disturbance; Stress, Psychological

Summary: this is a randomized pilot study of the use of cognitive behavior therapy versus observation to treat functional hypothalamic amenorrhea, often termed stress-induced anovulation.

the study enrollment was completed in 2003. the study results are being analyzed.

Eligibility criteria:
inclusion criteria: * women with functional hypothalamic amenorrhea * day awake / night asleep schedule exclusion criteria: * eating disorders, depression, excessive exercise or any other cause of amenorrhea and anovulation other than functional hypothalamic amenorrhea * weight loss greater than 10 pounds when amenorrhea developed * running more than 10 miles per week or exercising more than 10 hours per week

Keywords: functional hypothalamic amenorrhea stress induced anovulation
the use of colloid versus crystalloid in post-operative pediatric cardiac patients for fluid resuscitation

Conditions: Cardiac Diseases

Summary: the purpose of the study is to help determine if either crystalloid solution or colloid solution is more advantageous as a resuscitative fluid in post-operative pediatric cardiac patients.

the study is designed to help detect if there is an advantage in giving one type of resuscitative fluid versus another in the setting of post-operative pediatric cardiac patients. the two types of fluid being compared are crystalloid solution (normal saline) and colloid solution (5% albumin). the primary outcome measurement will be how much volume of each type of fluid will be required in order to maintain hemodynamic stability as determined by mean arterial blood pressure within predetermined parameters. other secondary outcomes will include determinations of lactate clearance, inotropic support requirements, urine output, peripheral and pulmonary edema that occurs post-operatively, and the over all costs for each fluid based on number of required boluses and number of hours on mechanical ventilation.

Eligibility criteria:
inclusion criteria: * congenital heart defect with two ventricle anatomy and physiology * ages: 0 - 36 months of age exclusion criteria: * history of bleeding disorder * history of renal disorder

Keywords: crystalloid colloid pediatric cardiac resuscitation postoperative
basic study of combination therapy based on apcc-induced fvlli activation in hemophilia a patients with inhibitors

Conditions: Hemophilia A With Inhibitor

Summary: using whole blood samples and plasma samples obtained from some hemophilia a patients with inhibitors, the investigators will perform the coagulation assessment in the co-presence of apcc and factor viii by comprehensive coagulation assays and flow chamber analysis under blood flow conditions.

comprehensive coagulation assays using recently popular rotational thromboelastometry (rotem), factor xa/thrombin/plasmin generation test, and coagulation wave analysis and recently developed flow chamber system under blood flow conditions (t-tas®) will be used. a bypassing agent, apcc (feiba®) and recombinant factor viii (advate®) will be added ex vivo to whole blood and plasma samples from patients with hemophilia a with inhibitors to compare with the coagulation effects of apcc in the presence of factor viii and those of apcc in its absence under the conditions close to the physiological condition. furthermore, the difference in the coagulation effects by the difference in inhibitor epitopes will be examined.

Eligibility criteria:
inclusion criteria: * patients with hemophilia a with inhibitors (inhibitor titer; \>0.5 bethesda u/ml) * patients with agreement consents with the patients signatures exclusion criteria: * patients that do not fill the conditions described above

Keywords: hemophilia a inhibitor bypassing therapy factor viii
evaluation of the efficacy of the watch your weight during holidays program for the prevention of body weight gain in mexican adults.

Conditions: Obesity; Weight Gain; Overweight

Summary: obesity is the main risk factor for the development of chronic-degenerative diseases in mexico. due to the difficulty of treating obesity, prevention is urgently needed. the holidays are the festive period with the greatest impact on adult body weight. evidence from observational studies has shown that more than 50% of the annual weight is gained during this period. however, few preventive interventions have been carried out worldwide. the present work will evaluate the efficacy of the watch your weight during holidays program on the prevention of weight gain during 8 weeks in comparison with the control group in mexican adults. the study will be a randomized clinical trial. it will have two intervention groups: 1) watch your weight during holidays program and 2) control group (minimal intervention). weight, height, body mass index, waist circumference, kilograms of body fat, fat mass index, cm2 of abdominal fat, blood pressure and perception of health-related quality of life will be measured in 64 volunteers, at the beginning and after 8 weeks of participating in watch your weight during holidays program. for comparisons between groups, student's t-tests or mann-whitney's u-tests will be performed, according to the type of sample distribution. the primary variable of the study will be the change in body weight. the secondary variables will be the change in body mass index, waist circumference, kilograms of fat mass, fat mass index, cm2 of abdominal fat, blood pressure and aspects of perception of quality of life related to health.


Eligibility criteria:
inclusion criteria: * adults (≥18 and ≤60 years of age). * residents of the city of hermosillo, sonora. * bmi ≥ 23 and ≤ 40. * availability of time to participate in the study, including initial and final measurements. * have a device with access to whatsapp * accept not to carry out any other intervention outside of the one assigned in the study during the 8 weeks of the intervention. exclusion criteria: * have medical conditions due to previous diagnosis, which require the prescription of treatments that affect weight, such as diabetes and thyroid diseases. other exclusion criteria will be liver failure, cancer under treatment or at an advanced stage, a history of covid-19 that has required hospitalization, supplemental oxygen or left sequelae that contraindicate the intervention; psychiatric conditions, eating disorders, etc. * use of drugs or substances with an effect on weight, for example, metformin, orlistat, corticosteroids, etc. * use of addictive substances such as drugs of abuse * previous bariatric surgery. * being a participant in another intervention or treatment for the management of obesity. * weight loss \> 5% of total body weight in the last 4 months. * having plans to become pregnant within the study period, currently pregnant or breastfeeding. * another family member has agreed to participate in the study. * illiteracy

Keywords: holiday season prevention
potential causes of retained items during surgery

Conditions: Foreign Bodies; Surgical Sponge, Retained

Summary: to understand and analyze the potential causes of retained items (sponge and instruments) during surgery, which include room preparations, initial count, adding sponges, removing sponges, first closing count, final closing count.


Eligibility criteria:
inclusion criteria: • operating room staff of hail hospital cluster exclusion criteria: • none
subcutaneous botulinum toxin for cutaneous allodynia - enriched responder trial

Conditions: Pain

Summary: superficial injection of botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. the investigators have observed prolonged profound analgesia following subcutaneous superficial injection of botulinum toxin type a (bta) in patients with certain types of neuropathic pain. the investigators propose to study if addition of bta extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

patients with post-herpetic neuralgia, complex regional pain syndrome, and post-surgical neuromatous pain patients have marked cutaneous allodynia. touching their skin with normally non-painful stimuli results in pain. injected local anesthetics are often effective in providing temporary relief. in the course of clinical practice the investigators have observed that a number of patients with cutaneous allodynia have had marked persistent benefit from subcutaneous injection of botulinum toxin type a. rather than killing targeted neurons, botulinum toxin type a inhibits release of acetylcholine from cholinergic nerve terminals in a prolonged but ultimately reversible manner. neuropathic pain and its hallmark allodynia are classically difficult to treat. standard treatment with tricyclic antidepressants, anti-epileptic drugs, opiates and spinal cord stimulation is frequently disappointing leaving patients with refractory pain. surgical or percutaneous ablation of involved nerves has fallen out of favor among many due to disappointing results. a pilot study is needed to assess the efficacy of superficially injected botulinum toxin type a for treatment of cutaneous allodynia and spontaneous pain among patients with neuropathic pain.

Eligibility criteria:
inclusion criteria: * moderate to severe pain (greater than 2/10) of duration more than 6 months despite previous therapy, excluding botox injection * the patient exhibits at least 80% pain relief following injection of local anesthetic subcutaneously into scar as assessed by change in nrs * patient reports more than 3 weeks of greater than 50% pain relief from previous botox injection * the patient reports the presence of hyperalgesia, allodynia, dysesthesia, or hypoesthesia surrounding the scar in the absence of the botox injection * age 18-100 * ability to read, write, and converse in english, provide informed consent, and follow study procedures exclusion criteria: * any neuromuscular disorder such as myasthenia gravis, eaton lambert, muscular dystrophy * any ongoing legal action related to their pain * allergy to local anesthetics * any ongoing disability claim * currently being treated for any severe psychiatric disorder, including anxiety or depression * history of any adverse reaction to botulinum toxin * history of botulism * untreated infection * coagulopathy * (females) - positive pregnancy test * surgery in the last 6 months